Loading...

Kiniksa Pharmaceuticals, Ltd.

KNSANASDAQ
Healthcare
Biotechnology
$33.04
$-0.71(-2.10%)

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Competitors & Peer Comparison

See (KNSA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
KNSA$33.04-2.10%2.4B660.80$0.05N/A
VRTX$388.94-1.56%99.7B27.63$14.07N/A
REGN$572.38-2.90%59.6B14.43$39.67+0.46%
ALNY$443.64-2.36%58.2B-181.08-$2.45N/A
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ARGX$677.32+2.62%41.4B34.43$19.67N/A
BNTX$105.07-5.24%25.3B-63.30-$1.66N/A
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
SMMT$26.27+0.27%19.5B-26.01-$1.01N/A
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

KNSA vs VRTX Comparison August 2025

KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 2.4B. In comparison, VRTX has a market cap of 99.7B. Regarding current trading prices, KNSA is priced at $33.04, while VRTX trades at $388.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 660.80, whereas VRTX's P/E ratio is 27.63. In terms of profitability, KNSA's ROE is +0.01%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, KNSA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check VRTX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;